Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury by Bejaoui, Mohamed et al.
Research Article
Polyethylene Glycol Preconditioning: An Effective Strategy to
Prevent Liver Ischemia Reperfusion Injury
Mohamed Bejaoui,1 Eirini Pantazi,1 Maria Calvo,2 Emma Folch-Puy,1 Anna Serafín,3
Gianfranco Pasut,4,5 Arnau Panisello,1 René Adam,6 and Joan Roselló-Catafau1
1Experimental Pathology Department, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Rossello 161,
Barcelona, 08036 Catalonia, Spain
2Advanced Optical Microscopy Unit CCiTUB, Science and Technology Center, Faculty of Medicine, University of Barcelona,
C/Casanova 143, Barcelona, 08036 Catalonia, Spain
3Platform of Laboratory Animal Applied Research, Barcelona Science Park, Barcelona, 08028 Catalonia, Spain
4Pharmaceutical and Pharmacological Sciences Department, University of Padova, 35131 Padova, Italy
5Veneto Institute of Oncology (IOV), IRCCS, 35128 Padova, Italy
6Hepato-Biliary Centre, Paul Brousse Hospital, Inserm U776, Paris-Sud University, Villejuif, 75008 Paris, France
Correspondence should be addressed to Joan Rosello´-Catafau; jrcbam@iibb.csic.es
Received 27 August 2015; Revised 29 October 2015; Accepted 2 November 2015
Academic Editor: Ryuichi Morishita
Copyright © 2016 Mohamed Bejaoui et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Hepatic ischemia reperfusion injury (IRI) is an inevitable clinical problem for liver surgery. Polyethylene glycols (PEGs) are water
soluble nontoxic polymers that have proven their effectiveness in various in vivo and in vitro models of tissue injury. The present
study aims to investigate whether the intravenous administration of a high molecular weight PEG of 35 kDa (PEG 35) could be
an effective strategy for rat liver preconditioning against IRI. PEG 35 was intravenously administered at 2 and 10mg/kg to male
Sprague Dawley rats. Then, rats were subjected to one hour of partial ischemia (70%) followed by two hours of reperfusion.
The results demonstrated that PEG 35 injected intravenously at 10mg/kg protected efficiently rat liver against the deleterious
effects of IRI. This was evidenced by the significant decrease in transaminases levels and the better preservation of mitochondrial
membrane polarization. Also, PEG 35 preserved hepatocyte morphology as reflected by an increased F-actin/G-actin ratio and
confocal microscopy findings. In addition, PEG 35 protective mechanisms were correlated with the activation of the prosurvival
kinase Akt and the cytoprotective factor AMPK and the inhibition of apoptosis.Thus, PEGmay become a suitable agent to attempt
pharmacological preconditioning against hepatic IRI.
1. Introduction
Ischemia reperfusion injury (IRI) is inherent to surgical pro-
cedures such as liver resection and liver transplantation. The
deleterious effects caused by IRI are the main cause of graft
primary nonfunction and dysfunction [1]. Many strategies
have been developed to protect against IRI such as ischemic
preconditioning (IPC) and the use of different drugs. How-
ever, these strategies did not prove their effectiveness in
clinical setting and efficient treatments are still lacking.
Polyethylene glycols (PEGs) are water soluble nontoxic
polymers with different molecular weights and properties
that have been extensively used in numerous applications
(cosmetic, foods, pharmacy, and biomedicine) [2]. Also,
PEGs have been found to exert beneficial effects in various in
vivo and in vitromodels of tissue injury [3–8]. Recently, it has
been demonstrated that intravenous administration of high
molecular weight PEG of 20 and 35 kDa protected rat heart
against reperfusion injury and steatotic livers against cold IRI,
respectively [9, 10].Theprotective effectswere associatedwith
decreased vascular permeability, decreased oxidative stress,
and inhibition of cell death [8, 11].
The aim of the present study is to examine the potential
benefits of prophylactic intravenous administration of PEG
35 in order to prevent warm IRI in rat liver as well as to inves-
tigate the underlying mechanisms.
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2. Materials and Methods
2.1. Animals. Male Sprague Dawley rats (250–300 g) were
purchased from Charles River (France) and housed in a
temperature and humidity controlled room under a constant
12-hour light/dark cycle. Animals had free access to water ad
libitum and rat chow (standard laboratory pelleted formula
A04, Panlab, Barcelona, Spain). This study was performed in
accordance with European Union Directive 2010/63/EU for
animal experiments and approved by the Ethics Committees
for Animal Experimentation of the University of Barcelona
(number 696/14).
2.2. Surgical Procedure. All the procedure was performed
under isoflurane inhalation (induction dose of 5% and main-
tenance dose of 1.5–2%). Also, analgesia was applied before
surgery by subcutaneous injection of buprenorphine at the
dose of 0.05mg/kg. After laparotomy, ischemia was induced
by occlusion of the hepatic artery and portal vein of the left
and median lobes using an atraumatic microvascular clip
(70% ischemia). After one hour of ischemia, liver reperfusion
was established by removal of the clamp and the abdomen
was sutured. Then, rats were kept in clean cages with free
access to water and standard rodent chow. After 2 h of
reperfusion, animals were sacrificed by cervical dislocation
under isoflurane anaesthesia for blood and tissue collection.
Sham operated rats underwent the same procedure without
vascular clamping.
2.3. Drug Treatment. PEG35was kindly provided by Institute
Georges Lopez (IGL). PEG 35 was dissolved in phosphate
buffer saline (PBS) and administrated 10min before liver
ischemia by intravenous bolus via the penile vein at the
concentration of 2mg/kg or 10mg/kg using PEG 35 solution
of 1 g/L and 5 g/L, respectively. For intravital microscopy
study, PEG 35 was fused with fluorescein (PEG-FITC) as
previously described by Mero et al. [12].
2.4. Experimental Groups. Rats were randomly distributed
into four groups as follows.
Group 1 (Control: 𝑛 = 6). Midline incision was performed
and hepatic pedicle was dissected. Then, 500𝜇L of PBS was
injected intravenously via the penile vein and abdomen was
sutured. After 2 h, rats were sacrificed for blood and sample
collection.
Group 2 (IR 2 h, 𝑛 = 6). Rats were pretreated with 500 𝜇L of
PBS intravenously and then subjected to one hour of ischemia
followed by 2 h of reperfusion. Then, animals were sacrificed
and plasma and liver samples were collected.
Group 3 (PEG 2mg/kg, 𝑛 = 6). It is the same as group 2 but
rats were pretreated with intravenous administration of PEG
35 at the dose of 2mg per kg body weight.
Group 4 (PEG 10mg/kg, 𝑛 = 6). It is the same as group 2 but
rats were pretreated with intravenous administration of PEG
35 at the dose of 10mg per kg body.
2.5. Biochemical Determinations
2.5.1. Hepatic Injury. Plasma levels of alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) were
measured using a commercial kit from RAL (Barcelona,
Spain) according to manufacturer’s protocol.
2.5.2. Glutamate Dehydrogenase Activity. GLDH activity was
determined using a commercial kit (GLDH, Randox lab-
oratories Ltd., Crumlin, UK) by quantifying the decrease
in absorbance at 340 nm according to the manufacturer’s
protocol.
2.5.3. Determination of Nitrites and Nitrates. Nitric oxide
levels were measured as nitrate plus nitrite (NOx) in tissue
samples using a commercial colorimetric assay kit (Cayman
Chemical Co., Ann Arbor, MI, USA).
2.6. Western Blot Analysis. Liver tissue was homogenized in
HEPES buffer and 50 𝜇g of protein was separated on 6–10%
SDS-PAGE gels and transferred to PVDF membranes. Mem-
braneswere then incubated overnight at 4∘Cusing the follow-
ing antibodies: anti-eNOS (BD Transduction Laboratories,
Lexington, KY, USA), anti-phosphorylated Akt, anti-total
and anti-phosphorylated AMPK (Cell Signaling Technology
Inc., Beverly, MA, USA), and anti-𝛽-actin (Sigma Chemical,
St. Louis, MO, USA). The corresponding secondary anti-
body was then added for 1 hour at room temperature and
membranes were developed using the enhanced chemilu-
minescence reagents from Avision (Advansta, Menlo Park,
CA, USA). Signals were quantified by scanning densitometry
using the Quantity One software for images analysis. Results
were expressed as densitometric ratio between the protein of
interest and the correspondentControl (𝛽-actin, total AMPK,
and total Akt).
2.7. Histology. Formalin-fixed paraffin-embedded liver tis-
sues were cut in 5 𝜇m sections and stained with hematoxylin
and eosin according to standard procedures. Images were
analysed by an independent investigator in blind manner.
2.8. F-Actin/G-Actin Ratio Measurements. To analyse the
levels of F-actin andG-actin, liver sampleswere homogenized
with PHEM buffer (60mM Pipes, 20mM HEPES, 10mM
EGTA, 2mMMgCl
2
, 1% Triton X-100, and pH 7.0) and ultra-
centrifuged (48.000 rcf) at 4∘C for 5min to separate both
fractions. Supernatant, containing G-actin, was collected; the
F-actin pellet was washed twice with cold PHEM buffer and
then dissolved in 1x SDS sample buffer. Equivalent amounts
of proteins were separated by 10% SDS-PAGE, and F-actin
and G-actin were determined by western blot and quantified
by scanning densitometry. The F-actin/G-actin ratio was
calculated.
2.9. IntravitalMicroscopy. Ratswere anesthetizedwith isoflu-
rane inhalation, laparotomized, and put in a prone position
over a cover slip mounted on the stage of Leica TCS SP5 reso-
nant scanmultiphoton confocalmicroscope (LeicaMicrosys-
temsHeidelbergGmbH) equippedwith an incubation system
Oxidative Medicine and Cellular Longevity 3
1400
1200
1000
800
600
400
200
0
A
ST
 (U
/L
)
Control IR 2h
∗
∗
∗#+
PEG 10mg/kgPEG 2mg/kg
(a)
A
LT
 (U
/L
)
∗
∗
∗#+
1250
1000
750
500
250
0
IR 2h PEG 10mg/kgPEG 2mg/kgControl
(b)
IR 2h PEG 10mg/kg
(c)
Figure 1: Hepatic injury after ischemia reperfusion. PEG 35 at 10mg/kg decreases AST (a) and ALT (b) levels and the number of necrotic
areas as shown by histological findings (eosin/hematoxylin staining) (c). Data represent mean ± SEM. ∗𝑃 < 0.05 versus Control, #𝑃 < 0.05
versus IR 2 h, and +𝑃 < 0.05 versus PEG 2mg/kg.
with temperature control, HCX IR APO L 25x water immer-
sion objective (Numerical Aperture 0.95), resonant scanner
at 8000 lines/s, and a near-infrared Titanium:Sapphire laser
(MaiTai, Spectra-Physics) for two-photon excitation running
at 800 nm.
The following vital dyes were injected intravenously as
indicated: Hoechst 33342 trihydrochloride (12mg/kg, Invi-
trogen, H3570) for DNA-nuclei staining; Rhodamine 123
(0.11mg/kg, Sigma, R8004) for mitochondrial membrane
potential dye; Evans Blue (20mg/kg, Sigma, E2129-10), a
bulk fluid-phase albumin marker that enhances contrast of
plasma; and PEG 35 conjugated with fluorescein isothio-
cyanate (PEG-FITC).
Images were acquired with resonant scan at 8000 lines/
second.
2.10. Confocal Fluorescence Microscopy. Liver was fixed, cry-
oprotected with sucrose, embedded in OCT, and frozen on
a copper plate on dry ice. Ten-micrometer cryosections were
cut in a cryostat and postfixed in 4% buffered paraformalde-
hyde for 10min and then permeabilized with PBS containing
0.1% Triton X-100 and 1% BSA for 30min. For actin visualiza-
tion, the slides were incubated with TRITC-Phalloidin (dilu-
tion 2𝜇M, Sigma) in PBS with 1% BSA and 0.2% Triton X-100
for 30min. Slides were washed three times for 15min with
PBS. The last PBS wash included Hoechst 33342 (dilution
1mM, Invitrogen). Finally, cryosections were mounted using
Mowiol (Calbiochem). Confocal images were acquired with
Leica TCS SP5 laser scanning microscope. Hoechst 33342
and Phalloidin-A555 images were acquired sequentially using
405 and 561 nm laser lines. The confocal pinhole was set at
1 airy unit and when 3D reconstruction was required stacks
of images every 0.3mm were acquired. The hepatocytes size
(in 𝜇m2) and circularity as (4𝜋 × Area)/Perimeter2 (based
on Phalloidin staining) were quantified on ImageJ. The red
channel (Phalloidin-A555 staining) was processed to seg-
ment hepatocytes. Hepatocytes were selected and size and
circularity were measured (in 1.5mm2 of each sample). A
value of 1.0 indicated a perfect circle; as the value approached
0.0, it indicated a more polyhedral shape.
2.11. Statistical Analysis. Data are expressed as means ± stan-
dard error and were compared statistically by the one-way
analysis of variance, followed by the Tukey test (GraphPad
Prism software). 𝑃 < 0.05 was considered significant.
3. Results
In order to evaluate the effect of PEG 35 in liver IRI, we firstly
determined the liver damage through transaminases levels
and hepatic histology after 1 hour of ischemia followed by
2 hours of reperfusion. As shown in Figures 1(a) and 1(b),
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Figure 2: Mitochondrial damage after liver ischemia reperfusion. PEG 35 at 10mg/kg decreases glutamate dehydrogenase (GLDH) levels (a)
and preserves mitochondrial polarization status (b) (mitochondrial membrane potential dye Rhodamine 123 (green color), the nuclei dye
Hoechst (blue color), and the plasma albumin dye Evans blue (red color)). Data represent mean ± SEM. ∗𝑃 < 0.05 versus Control; #𝑃 < 0.05
versus IR 2 h.
IR group led to significant increases in transaminases levels
compared to Control group, which was prevented when
rats were pretreated with intravenous injection of PEG 35
at 10mg/kg. By contrast, no significant differences were
observed when PEG 35 at 2mg/kg was administered. His-
tological findings shown in Figure 1(c) were in accordance
with liver injury parameters. Animals subjected to IR showed
extensive areas of coagulative hepatic necrosis with disrup-
tion of hepatic cords and haemorrhage randomly distributed
throughout the hepatic parenchyma. PEG at 10mg/kg
reduced the extent and the number of necrotic areas.
It is well known that hepatic damage after reperfusion
is associated with mitochondrial alterations. For this reason,
we measured GLDH activity to assess mitochondrial injury
after two hours of reperfusion. As indicated in Figure 2(a),
the increase in GLDH levels observed in ischemic group was
prevented in PEG 10mg/kg group. No changes were observed
in PEG 10mg/kg versus Control. By contrast, pretreatment
with PEG 35 at 2mg/kg was not sufficient to protect mito-
chondria against IRI. Also, we performed intravital multi-
photon microscopy in living rats at one hour of reperfusion
to evaluate mitochondrial polarization status using Rh123
(Figure 2(b)). In the livers of Control rats, bright punctate
Rh123 fluorescence was observed representing cells with
polarized mitochondria. However, livers from ischemic rats
showed a dimmer diffuse cytosolic fluorescence indicating
mitochondrial depolarization. Importantly, when rats were
pretreated with PEG 35 at 10mg/kg, mitochondrial depolar-
ization was lessened after ischemia and totally reverted after
reperfusion.
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Figure 3: Effect of PEG 35 on Akt, AMPK, eNOS activation, and NO generation. PEG 35 preconditioning at 10mg/kg enhances AMPK and
Akt activation and increases nitrite/nitrate levels without any effect on eNOS. Western blot and densitometric analysis of phosphorylated
Akt/b-actin (a), phosphorylated AMPK/total AMPK (b), eNOS/b-actin (c), and biochemical determination of nitrite+nitrate levels in liver
tissue (d). Data represent mean ± SEM. ∗𝑃 < 0.05 versus Control; #𝑃 < 0.05 versus IR 2 h.
Next, we investigated the potential signalling mecha-
nisms involved in the beneficial effects of PEG 35 pretreat-
ment. In this sense, it has been reported that protein kinase
B (Akt) is a prosurvival protein that decreases apoptosis in
models of IRI [13]. Also, it is well known that AMPK is a
cellular metabolic sensor that switches the cell to an energy
conserving status under ischemic conditions [14]. Our results
show that PEG 35 administration at the dose of 10mg/kg
induced a significant activation of both Akt and AMPK
(Figures 3(a) and 3(b), resp.).
Both AMPK and Akt have been shown to activate
endothelial nitric oxide synthase (eNOS) [15]. However, no
changes in eNOS activation were found when PEG was used
(Figure 3(c)) although significant increases in nitrites/ni-
trates levels in liver tissue were observed (Figure 3(d)).
Given the central role played by apoptosis in liver IRI,
we evaluated the effects of PEG 35 on hepatic apoptosis by
measuring caspases 3 and 9. As shown in Figure 3, PEG
10mg/kg promoted a significant reduction of cleaved cas-
pases 3 and 9. No significant differences were found regard-
ing pretreatmentwith PEG 35 at 2mg/kg although a tendency
towards a decrease was observed when compared to IR group
(Figure 4).
In addition, we studied the potential PEG effects on
cytoskeleton. Confocal microscopy images of F-actin stained
with Phalloidin showed that, in PEG 35 pretreated livers,
filamentous actin associated with the membrane microfil-
amentous network and the pericanalicular band are kept
preserved (Figure 5(a)). Also, morphology of hepatocytes in
ischemic livers was compromised after ischemia reperfusion
as shown in quantification of hepatocytes size and circularity
(Figures 5(b) and 5(c)). Increase in size and circularity indi-
cates that hepatocytes have swollen and lost their shapewhich
was less evident in case of PEG treated livers. Moreover,
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Figure 4: Effect of PEG 35 on liver apoptosis after ischemia reperfusion. PEG 35 at 10mg/kg reduced the levels of apoptotic proteins caspases
3 and 9. Western blot and densitometric analysis of cleaved caspase 3/procaspase 3 (a) and cleaved caspase 9/procaspase 9 (b). Data represent
mean ± SEM. #𝑃 < 0.05 versus IR 2 h; +𝑃 < 0.05 versus PEG 2mg/kg.
IRI induced an important decrease of F-actin/G-actin ratio,
which was significantly prevented when PEG 10mg/kg was
administered, as it is indicated in Figure 5(d). Also, it has been
reported that activation of p38 leads to cytoskeletal changes
by increasing the hepatocyte F-actin content after IRI [16].
For this reason, we investigated whether the cytoskeleton
preservation observed with PEG pretreatment was correlated
with changes in p38 phosphorylation status. Indeed, our
results showed that PEG preconditioning increased p38
activation (Figure 5(e)).
Finally, we performed intravital microscopy using PEG-
FITC in order to study its localization in liver tissue. We
observed that PEG was still present in liver vascular bed
after one hour of ischemia and one hour of reperfusion,
which is showed in the additional movie file (see Addi-
tional File 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9096549).
4. Discussion
IRI is an important cause of liver damage occurring during
surgical procedures including hepatic resection and liver
transplantation and represents the main cause of graft dys-
function and primary nonfunction after transplantation [17].
PEGs are water soluble nontoxic polymers that are known
to play an important role in the cytoprotection against
ischemic damage. Recent studies have shown that PEG exerts
anti-inflammatory, antiapoptotic, immunosuppressive, and
membrane stabilization effects [4, 5, 8, 18–20]. From this
perspective, it is reasonable to expect that PEG administra-
tion may be an effective therapeutic strategy against IRI. In
this study, we demonstrate, for the first time, that PEG 35
preconditioning protects rat liver against warm IRI.
Wehave focused our study onPEGwithmolecularweight
of 35 kDa because it has been previously demonstrated that
PEG 35 was effective in preventing cold IRI in liver when it
was added to organ preservation solutions [21–23].Moreover,
PEG 35 has been shown to protect renal cells against cold
ischemia [24]. Also, we recently evidenced that PEG 35
addition to washout solution protected cold stored livers
against reperfusion injury [25]. However, PEGs with different
molecular weights such as PEG 8 [11] or PEG 20 [8, 9] might
also be useful for conferring protection against IRI.
In order to achieve an efficient hepatoprotection, the
most suitable concentration of PEG 35 was 10mg/kg. This
concentration was well tolerated as Control rats injected with
PEG 35 at 10mg/kg did not present any liver damage (data
not shown).
The beneficial effects induced by PEG 35 are mainly
associated with the preservation of the mitochondrial status,
as revealed by decreases in GLDH levels and intravital
microscopy findings. Sincemitochondria are sensitive targets
for damage during IRI [23, 24], the lessened hepatic injury
observed when PEG 35 was administered at 10mg/kg coin-
cided with increased mitochondrial preservation.
We next determined whether PEG 35 beneficial effect
could be related to the activation of protective cell signalling
pathways. Our results showed that PEG 35 at 10mg/kg con-
tributes to AMPK and AKT activation.These facts are in line
with previous reports showing that PEG 20 protects against
heart ischemia through AKT activation [7, 8] and PEG 35
protects rat liver against reperfusion injury, in part, through
AMPK activation [9]. These observations suggest that PEG
protective effects are not only related to its known role as
an oncotic support but also related to its pharmacological
properties.
Akt and AMPK activation have been related to apoptosis
inhibition in many models of IRI [15, 26, 27]. As it was
expected, PEG 35 at 10mg/kg prevented caspase 3 and cas-
pase 9 activation. These observations are in line with results
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Figure 5: PEG 35 preconditioning contribution to cytoskeleton preservation. Images of confocal microscopy show that, in PEG 35 pretreated
livers, filamentous actins (red) and hepatocytes morphology were better preserved when compared with nontreated ones. Also, PEG 35
pretreatment at 10mg/kg enhances significantly F-actin/G-actin ratio and phospo-p38 protein levels. Confocal microscopy for F-actin (a)
and determination of hepatocyte size (b) and hepatocyte circularity (c) and western blot and densitometric analysis of F-actin/G-actin (d)
and phosphorylated p38 (e). Data represent mean ± SEM. ∗𝑃 < 0.05 versus Control, #𝑃 < 0.05 versus IR 2 h, and +𝑃 < 0.05 versus PEG
2mg/kg.
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observed by Malhotra et al. who demonstrated that PEG 15–
20 protected cardiac myocytes from hypoxia and reoxygena-
tion induced apoptosis [8]. Moreover, we have previously
reported that PEG 35 addition to preservation solutions acts
as an oncotic agent ameliorating organ graft preservation by
reducing apoptosis in rat liver transplantation [28].
Nitric oxide (NO) is a gaseous vasodilator implicated in
the regulation of hepatic microcirculation, which is impaired
upon IRI [25]. In this sense, we found that PEG 35 at 10mg/
kg significantly increased NOx levels and this was not corre-
lated with eNOS activation. This observation is concomitant
with a previous published report showing that PEG induced
arteriolar dilatation which was not correlated to eNOS
activation [26]. However, we have recently evidenced that the
benefits of PEG in IRI were associated closely with eNOS
activation [8, 9]. Thus, more investigations are needed to
elucidate the precisemechanisms of NO generationmediated
by PEG.
Structural alterations of the cytoskeleton following ische-
mia reperfusion have been reported to cause disturbances
of intracellular transport processes and cell motility and
microcirculation leading to organ dysfunction [29–32]. In
liver cells, F-actin is a relevant component of liver cytoskele-
ton which forms microfilaments involved in intracellular
transport processes, such as exocytosis and endocytosis,
maintenance of cell shape, and canalicular motility respon-
sible for bile flow [25, 31, 33, 34]. In this context, we have
explored whether PEG 35 pretreatment could maintain the
cytoskeleton structure and preserve the morphological char-
acteristics of hepatocytes. Indeed, our present data confirmed
that F-actin/G-actin ratio is increased as a consequence
of PEG administration at 10mg/kg. Furthermore, confocal
microscopy findings confirmed that PEG contributes to the
regulation of endothelial cell barrier by rearranging the actin
cytoskeleton. Hepatocytes presented a more normal hex-
agonal morphology in livers pretreated with PEG 35 com-
pared with livers submitted to IRI. All of these observations
are consistent with a recent study in lung endothelial cells
evidencing that PEG 15–20 preserves the architecture of the
endothelial cytoskeleton [35]. Moreover, it has been dem-
onstrated that PEG induced membrane stabilization through
sarcolemmal lipid-raft architecture preservation [8]. These
published data suggested that PEG interactionwith cellmem-
brane (adhesion or intercalation) preserved the cytoskeleton.
In our study we further evidenced that PEG-induced-p38
MAPK activation may also be responsible for cytoskeleton
preservation. However, the precise mechanisms of how PEG
could affect cytoskeleton remain to be elucidated.
Currently, the proposed strategies against IRI rely on
surgical procedures such as IPC or on the use of pharmaco-
logical agents (pharmacologic preconditioning) [36]. IPC is
a well-established technique that consists of the application
of brief episodes of ischemia and reperfusion which cause
protection against the subsequent prolonged ischemic insult
[37]. However, this manipulation is not tolerated in most
operation rooms. Pharmacologic preconditioning consists of
the administration of drugs that block injurious pathways
directly or trigger endogenous protective mechanisms [36].
Although most of these drugs were effective in reducing IRI
in many experimental models, studies that evaluate their
efficacy in the clinical settings are still lacking. Moreover,
their benefits are limited to the specific drug activity and
their potential adverse effects. Compared to IPC and phar-
macologic preconditioning, PEG presents the advantages of
being safe and multitarget drug. Indeed, PEG effects are
associated with the majority of the events occurring during
IRI such as oxidative stress, mitochondrial preservation,
cytoskeleton protection, and the induction of prosurvival and
cytoprotective signaling pathways.
5. Conclusions
In conclusion, the present work evidences that intravenous
administration of PEG 35 is a useful tool for liver precondi-
tioning against the deleterious effects of IRI. Based on these
findings, PEG 35 administration could be a useful approach
in clinical settings.
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